lukas

St. Anna CCRI wants to develop new drug against Ewing sarcoma with international partners

St. Anna CCRI wants to develop new drug against Ewing sarcoma with international partners A three-year project aims to improve the long-term survival rate of patients with Ewing sarcoma. (Vienna, 22.02.2024) Ewing sarcoma is a very aggressive, rapidly metastasizing bone cancer. In Austria, five to eight children and adolescents are affected every year. The long-term

St. Anna CCRI wants to develop new drug against Ewing sarcoma with international partners Read More »

Investigating the Origins of Neuroblastoma and Nephroblastoma

Investigating the Origins of Neuroblastoma and Nephroblastoma (Vienna, 15.02.2024) The cellular changes leading to the development of cancer in children are still largely unknown, especially in the case of embryonal tumors. A new study led by Florian Halbritter, Principal Investigator at St. Anna Children’s Cancer Research Institute (St. Anna CCRI), aims to elucidate why certain genetic

Investigating the Origins of Neuroblastoma and Nephroblastoma Read More »

Today is International Childhood Cancer Day 2024

Wolf vs. Sheep – Game Release on International Childhood Cancer Day 2024 (Vienna, 15.2.2023) Today, we stand united under the golden ribbon – it’s International Childhood Cancer Day. A day to reflect on the fact that children aren’t simply „little“ adults, and their cancer journey demands dedicated research for tailored treatments. Bioinformatics plays a crucial role

Today is International Childhood Cancer Day 2024 Read More »

CML: A new combination therapy against resistant leukemia

CML: A new combination therapy against resistant leukemia (Vienna, 6.2.2024) In a new publication in the American Journal of Hematology, scientists at St. Anna Children’s Cancer Research Institute show a treatment option for chronic myeloid leukemia with highly resistant multiple mutations that have eluded previous therapies. Chronic myeloid leukemia (CML) is a slowly progressing cancer. It

CML: A new combination therapy against resistant leukemia Read More »

World Cancer Day 2024: Collaboration is Key

World Cancer Day 2024: Collaboration is Key (Vienna, 4.2.2024) Todays World Cancer Day reminds us of the urgent need for a collective effort in understanding Childhood Cancer and enhancing treatments for children bravely facing this formidable disease. In the realm of Childhood Cancer, international collaboration is paramount. Recognizing that individual nations working in isolation would not be

World Cancer Day 2024: Collaboration is Key Read More »

Neuroblastoma: Liquid biopsies to detect relapse of childhood cancer early

Neuroblastoma: Liquid biopsies to detect relapse of childhood cancer early (Vienna, 29.1.2024) Neuroblastoma mainly affects toddlers and young children – in the EU region there are 1500 new cases per year. Neuroblastoma is a malignant tumor of the peripheral nervous system and around 50% of patients are high-risk cases. Recurrences occur frequently, and conventional therapies are

Neuroblastoma: Liquid biopsies to detect relapse of childhood cancer early Read More »

CCRI – CeMM Collaboration Agreement

CCRI – CeMM Collaboration Agreement (Vienna, 22.01.2024) CCRI Directors Kaan Boztug and Jörg Bürger, and CeMM Directors Giulio Superti-Furga and Anita Ender have signed a partnership agreement which further strengthens scientific collaborations and training aspects.  CeMM’s research is strongly oriented towards medical needs and integrates research on fundamental biological processes with clinical expertise to gain

CCRI – CeMM Collaboration Agreement Read More »

VULSK Specialists Immerse in Clinical Trials Training at St. Anna CCRI under TREL Project

VULSK Specialists Immerse in Clinical Trials Training at St. Anna CCRI under TREL Project (Vienna, 17.11.2023) The EU-funded project TREL seeks to bridge gaps in research indicators and treatment outcomes by fostering collaboration, knowledge sharing, and skill development. This week, the St. Anna Childrens Cancer Research Institute warmly welcomed three specialists from Vilnius University Hospital Santaros Klinikos (VULSK)

VULSK Specialists Immerse in Clinical Trials Training at St. Anna CCRI under TREL Project Read More »

Network-based approaches open a new avenue to classify and treat rare diseases

Network-based approaches open a new avenue to classify and treat rare diseases Scientists at CeMM, Max Perutz Labs, and St. Anna Children’s Cancer Research Institute have achieved a significant advancement in the research of rare immune system disorders. Through a network-based approach, they have reclassified approximately 200 rare diseases. Initial comparisons with clinical data already

Network-based approaches open a new avenue to classify and treat rare diseases Read More »

Gene Mutation in the Immune System: Anti-Diabetes Drugs Make Immune Cells More Effective Again

Gene Mutation in the Immune System: Anti-Diabetes Drugs Make Immune Cells More Effective Again (Vienna, 31.08.2023) T cells are an essential component of the immune system – they fight foreign structures such as bacteria and viruses or cancer-related changes in cells. This defense reaction requires energy. Scientists led by the St. Anna Children’s Cancer Research Institute

Gene Mutation in the Immune System: Anti-Diabetes Drugs Make Immune Cells More Effective Again Read More »

“I think there are few things that so many people agree on as that it is good to support St. Anna CCRI!”

“I think there are few things that so many people agree on as that it is good to support St. Anna CCRI!” (Vienna, 28.08.2023) “Science Buster” and molecular biologist Martin Moder in brief: Why he supports the St. Anna Children’s Cancer Research Institute, how he deals with criticism, and what he currently likes doing best!

“I think there are few things that so many people agree on as that it is good to support St. Anna CCRI!” Read More »